By: MARILYNN MARCHIONE – AP Medical Writer

For women who have struggled with the symptoms of menopause but are fearful of taking risky hormone pills, there is at last a bit of hope. Hormone skin patches and gels, it seems, are far less likely than pills to cause dangerous blood clots. At least that was the finding from a recently published French study.

Patches and gels are already known to be effective for relieving the hot flashes and sleep-interrupting night sweats that plague many women. No one knows whether they will prove safer than pills in terms of breast cancer, heart attack or stroke risk. A large study currently under way may answer that.

But if they do, it may soften some of the backlash against hormones since a landmark study in 2002 frightened many women away from their use. Critics of that study have long contended that it is the type of estrogen or progestin, the dosage, and the method of taking the hormones that may affect the health risks.

The French study, while not the final word, is the strongest proof yet that this may be true, said Dr. JoAnn Manson, chief of preventive medicine at Harvard-affiliated Brigham and Women’s Hospital in Boston. She has no financial ties to hormone drugmakers and just published a book giving women advice on hormone use.
Read more…

GREEN BAY, WI, April 18, 2007-Many women are choosing dietary supplements for the management of menopausal symptoms – especially since serious health concerns have been raised about hormone replacement therapy (HRT). Remifemin® black cohosh extract, the most extensively researched, non-prescription menopausal therapy has been found to safely and effectively reduce hot flashes, night sweats and irritability. Now, a study published in the International Journal of Cancer: 120, 1523-1528 (2007), has shown that this proprietary herbal product lowers the risk of breast cancer by as much as 60%.

“The standardized Remifemin® black cohosh extract has antiestrogenic, antiproliferative and antioxidant properties,” said Dr. Eckehard Liske, Director of the International Medical Department, Schaper & Bruemmer GmbH & Co KG, Salzgitter, Germany. “Rebbeck’s research suggests that Remifemin® may help in reducing the risk of breast cancer.”
Read more…

(NAPSI)-Weak, fragile bones and susceptibility to fractures-these are some of the painful consequences of the debilitating bone disease, osteoporosis. Currently, 10 million people suffer from osteoporosis in the United States and another 34 million are at risk of developing the disease. The Surgeon General has named osteoporosis a national health threat and estimated that by 2020 one in two Americans over the age of 50 will be at risk for fractures from osteoporosis or low bone mass.

There are several risk factors associated with the development of osteoporosis, including inadequate levels of vitamin D, a nutrient essential to the body’s absorption of calcium. Recent research has uncovered that over 70 percent of women over the age of 50 have low levels of vitamin D, and even women being treated for osteoporosis have low levels of the important vitamin. To address the need for greater awareness about low levels of vitamin D, Spirit of Women Hospital Network has teamed up with Dr. Marie Savard, an internationally recognized women’s health expert, to launch a new vitamin D risk assessment.
Read more…